A fatal case of myxedema coma

Myxedema coma is a rare clinical condition that represents severe hypothyroidism decompensation usually occurs in patient with long-standing undiagnosed hypothyroidism and is usually precipitated by infection and discontinuation of supplements treatment. Clinical symptoms are a mental decreased status, hypothermia, bradycardia, hypotension, hypoglycemia and hypoventilation. Thyroid hormone measurement allows the diagnosis. Protocols with rapid intravenous high doses of thyroid hormone, warming and mechanical ventilation may improve the prognosis. The purpose of the present article is to describe a fatal case of myxedema coma in elderly-woman occurring in the context of immunodefi ciency. Case Report A fatal case of myxedema coma Fatima Zahra El Bouazzaoui*, Imane Boubagura, Sana Rafi , Ghizlane El Mghari and Nawal El Ansari Department of Endocrinology, Diabetology and Metabolic Diseases, University Hospital of Marrakech, Marrakech, Morocco Received: 26 March, 2019 Accepted: 30 April, 2019 Published: 02 May, 2019 *Corresponding author: Fatima Zahra El Bouazzaoui, Department of Endocrinology, Diabetology and Metabolic Diseases, University Hospital of Marrakech, Marrakech, Morocco, E-mail:


Introduction
Myxedema coma is a very rare endocrine emergency as a result of a very low synthesis of thyroid hormone due to some precipitating factors such as infections, hypothermia, heart failure, stroke, trauma, digestive bleeding, poor compliance of prescribed thyroid medications and drugs like lithium, sedatives, anesthesia [1]. Elderly patients with cardiovascular diseases, mental problems, sepsis and hypothermia are in highest risk of mortality [2,3]. As the condition is rare and not well recognized, we have only little case reports and series [4]. Intravenous thyroid hormone is the main therapy associated with supportive measures and in case of patient with stress statement and adrenal insuffi ciency, glucocorticoids must be co-administrated, the rate of mortality in myxedema coma high at 30%-40% [5]. This rare complication of hypothyroidism must be well known by the clinicians to improve management of patient.

Case Presentation
A 61-year-old woman with an end-stage renal failure associated with type 2 diabetes, hypertension, military tuberculosis with pulmonary and peritoneal involvement under anti-bacillary treatment and autoimmune thyroiditis with discontinuation of L-thyroxine since 2 months. She was hospitalized in the emergency department for mental status alteration. At admission, here blood pressure: 120/70 mmhg, bradycardia at 54 bpm, hypothermia at 35 °C.
The patient presented with dry depilated skin, Vitiligo and generalized myxedema ( Figure 1). The Glasgow Coma Score was 10 (2/3/5) .No goiter or stiffness was found after examination. Her consciousness level worsened and the patient was transferred to intensive care unit.
The initial laboratory test showed a normochromic normocytic anemia without electrolyte disorders. However because of end-stage renal failure level, patient had urea at 1,07g/l and serum creatinine at 73 mg/l. Hepatic encephalopathy was eliminated as the liver function was normal. Thyroid hormones were altered with thyroid-simulating hormone (TSH) of 100 mU/L and free thyroxine (FT4) of 3.9 pmol/l and free thyiodotyronine (FT3) of 1.6 pmol/l. Baseline cortisol level was 133 ug/l. The synacthen test was not performed so the coexisting of adrenal insuffi ciency was not eliminated.
The alteration of consciousness required the performance of brain tomography to search the possibility of existence of stroke. We should notice that our patient had military tuberculosis that may involve the central nervous system and Myxedema coma's diagnosis was confi rmed and medical treatment was started. The patient was warmed gradually and oxygen was supplied via mask. Levothyrox 300 ug was administered via nasogastric tube on third day after admission.
Intravenous injection of bolus hydrocortisone 100 mg was given followed by 50 mg /6H intravenously. The patient was under antibacillary treatment that we had continued and she had received here usual hemodialysis session. The thyroid hormones levels did not be verifi ed since the patient's clinical condition has not improved and she died 3 days later.

Discussion
Myxedema coma (MC) is an extreme manifestation in patients with untreated hypothyroidism. The typical clinical manifestation includes decreased mental status, hypothermia, hypoventilation, bradycardia, hypotension, and hypoglycemia.
Physical fi ndings show myxoedematous face, which is characterized by generalized puffi ness, macroglossia, ptosis, and coarse [4]. Very few cases of MC have been reported till date, with the fi rst case reported in London in 1879 [6]. Given the rarity of MC, actual prevalence is unclear with the estimated incidence rate of 0.22 cases per million people per year [7].
The diagnosis could be delayed because diagnostic laboratory data may not be available in a timely manner during emergency presentation. Our patient was also reported to have delayed diagnostic despite she was presented with all common features of MC, because she has other medical history as miliary tuberculosis and end-stage renal failure that make the fi rst diagnostic suspected of a decreased mental status secondary to hyper uremia or central nervous system tuberculosis.
MC is a lethal endocrine emergency. Administration of thyroid hormone replacement is mainstay therapy. It is recommended that initial replacement should be levothyroxine given intravenously at a loading dosage of 200 to 400 ug.
The replacement dosage reduced to 1.6 ug/kg/d thereafter [8]. The therapy should be introduced without delay [8]. It is suggested that this hormone started intravenously because gastrointestinal absorption may be impaired in severe cases [9]. Some authors show benefi cial effects of combinaison of enteral levothyroxine and liothyronine and reported that this patient had a lower mortality rate than those who received levothyroxine alone [10,11]. However, levothyroxine injection and Liothyronine are currently unavailable in Morocco. Our patient was treated with gastric levothyroxine at a dosage of 300 ug/d.